Pharmacologic Inhibition of Macrophage Triglyceride Biosynthesis Pathways Does Not Improve Mycobacterium tuberculosis Control in Infected Mice
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae577 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Jennie Ruelas Castillo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Triglycerides, Macrophages, Antitubercular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Tuberculosis necrotic granulomas contain triglyceride-rich macrophages (foam cells) with reduced antimicrobial functions. We assessed the ability of 2 compounds to reduce the triglyceride content and Mycobacterium tuberculosis (Mtb) burden in infected human monocyte-derived macrophages and in the lungs of Mtb-infected C3HeB/FeJ mice: A-922500 (DGATi), an inhibitor of diacylglycerol O-acyltransferase 1, and LY2584702 (p70S6Ki), an inhibitor of p70 S6 kinase. DGATi and p70S6Ki significantly reduced the lipid content and bacillary burden in Mtb-infected macrophages. Each inhibitor reduced the cellular triglyceride content in bronchoalveolar lavage samples of Mtb-infected mice. After 6 weeks of treatment, p70S6Ki alone reduced the lung bacterial burden in Mtb-infected mice. However, DGATi alone and DGATi or p70S6Ki in combination with isoniazid did not reduce lung bacterial burden or alter lung inflammation. These findings provide further insight into the role of foam cells in tuberculosis pathogenesis and the utility of interventions targeting these cell populations as adjunctive host-directed therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine.
- Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Public Health Research Institute, Rutgers New Jersey Medical School, The State University of New Jersey, Newark.
- Internal Medicine Residency Program, National Capital Consortium, Walter Reed National Military Medical Center, Bethesda.
- Center for Translational Medicine, School of Pharmacy, University of Maryland.
- Department of International Health.
ORCID-Profile: Jennie Ruelas Castillo, Styliani Karanika, Babajide Shenkoya, Harley Harris, Mathangi Gopalakrishnan, Petros C Karakousis
Förderung
- NIAID NIH HHS
- NIH HHS
- NHLBI NIH HHS
- National Institutes of Health
Zitieren
APA
Ruelas Castillo, J., Guerrini, V., Quijada, D., Karanika, S., Neupane, P., Urbanowski, M. E., Shenkoya, B., Harris, H., Garcia, A., Yilma, A., Annunziata, H., Khan, R., Gopalakrishnan, M., Gennaro, M. L., & Karakousis, P. C. (2025). Pharmacologic Inhibition of Macrophage Triglyceride Biosynthesis Pathways Does Not Improve Mycobacterium tuberculosis Control in Infected Mice. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae577
Vancouver
Ruelas Castillo J, Guerrini V, Quijada D, Karanika S, Neupane P, Urbanowski ME, et al. Pharmacologic Inhibition of Macrophage Triglyceride Biosynthesis Pathways Does Not Improve Mycobacterium tuberculosis Control in Infected Mice. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae577
BibTeX
@article{RuelasCastillo2025,
author = {Ruelas Castillo, Jennie and Guerrini, Valentina and Quijada, Darla and Karanika, Styliani and Neupane, Pranita and Urbanowski, Michael E and Shenkoya, Babajide and Harris, Harley and Garcia, Andrew and Yilma, Addis and Annunziata, Hannah and Khan, Rehan and Gopalakrishnan, Mathangi and Gennaro, Maria L and Karakousis, Petros C},
title = {Pharmacologic Inhibition of Macrophage Triglyceride Biosynthesis Pathways Does Not Improve Mycobacterium tuberculosis Control in Infected Mice},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae577}
}
EUVIMED